Skip to content
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
Icône L&M 2L&M 2
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact
Icône L&M 3L&M 3
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
Icône L&M 2L&M 2
  • LIPOEDEME (L&M n°2 2026)
  • SUMMARY
  • EDITORIALS
  • PRATIQUES
  • ACTUALITÉS
  • RECHERCHE
  • VALEURS
  • ARCHIVES L&M
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact
Icône L&M 3L&M 3
  • SCLÉROTHÉRAPIE (L&M n°3 2026)
  • EVF Phlebology Leaders
  • PIL Papers
  • Industry Leaders
  • Contact

Tag: Lm1 2024 thème Tout savoir

Lm1 2024 thème Tout savoir

LM N°1/ 2024. OVERVIEW OF REGENLAB'S PATENTED TECHNOLOGIES. Andreas PIGNI. Legal Affairs, RegenLab SA. 

patents

OVERVIEW OF REGENLAB'S PATENTED TECHNOLOGIES Andreas PIGNI Legal Affairs, RegenLab SA INTRODUCTION RegenLab SA has established itself as a pioneer and leader in regenerative medicine, known for its innovative technologies that synergistically use platelet-rich plasma (PRP) in combination with various bioactive/therapeutic agents, thus providing solutions to [...].

  • TO BE A LEADER IN ANTI-AGING MEDICINE
  • QUALITY COMMUNICATION 
  • INNOVATIVE VISUAL OFFERS
  • STRONG DIGITAL COMMUNICATION FOR MANUFACTURERS
  • AN ORIGINAL AND SCIENTIFIC MULTIMEDIA EXPERTISE
  • THE L&M BRAND: A REFERENCE FOR AESTHETIC HEALTH PROFESSIONALS

Useful links

  • Contact
  • CGU
  • Blog

Social networks

Instagram Facebook-f

Website and mobile application designed by CAPROVE